REGN vs GILD
REGN and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | — | $212.04B |
| P/E (TTM) | 20.5 | 25.2 |
| P/B | — | 16.26 |
| P/S | — | 7.2x |
| Dividend yield | — | 1.89% |
| Revenue | $16.90B(TTM) | $30.99B(TTM) |
| Revenue growth (YoY) | 1.0% | 2.4% |
| Net income | $4.82B(TTM) | -$3.86B(TTM) |
| Earnings growth (YoY) | 2.1% | 1672.9% |
| EPS, diluted | $45.24(TTM) | $-3.13(TTM) |
| EBIT margin | 24.9% | 34.0% |
| ROE | 13.4% | 65.3% |
| ROIC | 9.2% | 25.7% |
| 1y total return | +41.7% | +47.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: REGN vs GILD
| Metric | REGN | GILD |
|---|---|---|
| End value | $26.9K | $29.7K |
| Total return | +169.3% | +197.3% |
| CAGR | +10.1% | +11.1% |
| Volatility | 32.3% | 25.6% |
| Sharpe | 0.33 | 0.38 |
| Sortino | 0.49 | 0.56 |
| Max drawdown | -59.7% | -30.5% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)